Neurovalens Expands Access to Modius Sleep for Veterans Through U.S. Department of Veterans Affairs (VA) Program

, /PRNewswire/ -- Neurovalens, a global leader in noninvasive neurostimulation technology, is making significant strides in addressing chronic insomnia among U.S. veterans. The company's FDA-cleared, drug-free insomnia treatment device, Modius Sleep, is now available to veterans through the U.S. Department of Veterans Affairs (VA) program.

Insomnia is a significant concern among veterans, with studies showing that nearly 40% of U.S. veterans experience clinical or subthreshold insomnia, a rate far higher than that of the general population (source). Beyond disrupted sleep, insomnia is linked to increased stress, cognitive impairment, and a higher risk of chronic health conditions, making effective solutions critical for veteran well-being. Source: https://jcsm.aasm.org/doi/10.5664/jcsm.9182

Developed by Neurovalens, Modius Sleep is an FDA-cleared, award-winning, drug-free device designed to treat chronic insomnia. Using advanced noninvasive neurostimulation, the device targets key brain regions responsible for sleep regulation, helping users fall asleep faster, stay asleep longer, and improve overall sleep quality.

Jason McKeown, MD, CEO of Neurovalens, commented:
"We are honored to make Modius Sleep available to veterans through the VA program. Sleep issues are a significant challenge for many veterans, and we are proud to offer an effective, drug-free solution that can have a meaningful impact on their health and well-being. This partnership with the VA is a testament to our commitment to improving lives through technology."

Veterans struggling with chronic insomnia can request Modius Sleep through their local VA healthcare provider or contact Neurovalens directly to explore how this FDA-cleared, drug-free solution can help improve their sleep and overall well-being.

About Modius Sleep
Neurovalens is a global health-tech company specializing in noninvasive neurostimulation solutions designed to address some of the world's most pressing health challenges. The company's FDA-cleared Modius technology targets the brain regions responsible for sleep and circadian rhythm regulation, using low-level electrical stimulation of the vestibular nerve to support better sleep, stress management, and overall well-being. Headquartered in Belfast, United Kingdom, Neurovalens is committed to advancing drug-free, neuroscience-driven therapies to improve health outcomes worldwide.

For more information, visit www.neurovalens.com/modiussleep

Contact: Kate Willis
[email protected]
+1 513-532-2378

SOURCE Neurovalens